Showing 1 - 6 of 6 Nutritional and Metabolic Conditions & Diseases

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

To determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting triglyceride levels in patients with fasting levels ≥500 mg/dL and ≤1500 mg/dL after 12 weeks of treatment. ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placeb ... Read more >

Status: Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

In patients with diabetes and high triglycerides, subjects will be given pemafibrate to help reduce triglycerides level and cardiovascular outcomes. ... Read more >

Status: Enrolling

Investigator: Dipan Shah

Study Coordinator: Bevin Lopez

Phone: 713.441.6537

The American Diabetes Association estimates that 25.8 million individuals or 8.3% of the United States population have diabetes mellitus (DM). Individuals with diabetes have an increased risk for cardiovascular disease (CVD) and CVD events accou ... Read more >

Status: Open Not Enrolling

Investigator: Mahendra Jain

Study Coordinator: Bela Jain

Phone: 281.485.3434

This is a phase 3b, 16-week, multicentre, multinational, 1:1 randomised, double-blind, active controlled, treat-to-target, parallel group trial with a 12-week run-in period comparing the effect and safety of fast-acting insulin aspart to NovoRap ... Read more >